In addition to its role in diagnostic subclassification, NPM1 mutation determines a subgroup of AML with favorable prognosis, though this is influenced by the presence or absence of certain concomitant mutations, in particular FLT3-ITD and DNMT3. Here, FLT3 is linked to acute myeloid leukemia.